机译:使用HCV基因型1B的DCV / ASV与DCV / ASV的无IFN的方案的疗效和耐受性
Ogaki Municipal Hosp Dept Gastroenterol 4-86 Minaminokawa Ogaki Gifu 5038502 Japan;
Ogaki Municipal Hosp Dept Gastroenterol 4-86 Minaminokawa Ogaki Gifu 5038502 Japan;
Ogaki Municipal Hosp Dept Gastroenterol 4-86 Minaminokawa Ogaki Gifu 5038502 Japan;
Otakano Mori Hosp Dept Gastroenterol Kashiwa Chiba Japan;
Kagawa Prefectural Cent Hosp Dept Hepatol Takamatsu Kagawa Japan;
Kagawa Prefectural Cent Hosp Dept Hepatol Takamatsu Kagawa Japan;
Teine Keijinkai Hosp Ctr Gastroenterol Sapporo Hokkaido Japan;
Komaki City Hosp Dept Gastroenterol &
Hepatol Komaki Japan;
Ehime Prefectural Cent Hosp Dept Gastroenterol Matsuyama Ehime Japan;
Saiseikai Niigata Daini Hosp Dept Hepatol Niigata Japan;
Saiseikai Suita Hosp Dept Gastroenterol Osaka Japan;
Saiseikai Suita Hosp Dept Gastroenterol Osaka Japan;
Aged patients; Chronic hepatitis C; Direct-acting antiviral; Sustained virologic response; Tolerability;
机译:使用HCV基因型1B的DCV / ASV与DCV / ASV的无IFN的方案的疗效和耐受性
机译:临床显着门诊高血压(第BaveNo 2)对ParitaPrevir,Ritonavir,ObsitaSvir,Dasbuvir和利巴韦林(Prod Plus R)的安全,耐受性和功效的影响,在实际群体的基因型1B HCV肝硬化患者中
机译:在先前用非结构蛋白5A抑制剂的方案治疗的基因型1B HCV患者中有或不含利韦韦林12周的LEDIPASVIR / SOFOSBUVIR的疗效
机译:六年随访中干扰素-α和利巴韦林联合治疗对HIV / HCV合并感染患者的疗效
机译:药效学参数对HIV-1感染的患者和HCV合并感染的HCV患者的临床结局预测的影响。
机译:HCV基因型1b感染的患者接受peginterferon Lambda-1aDaclatasvir和Ribavirin的三重组合治疗12周
机译:无肝硬化的基因型1B HCV感染患者中所有口服Emitasvir和Sofosbuvir的疗效和安全性